Dear JITC Readers,
It is a pleasure to welcome you to this edition of the JITC digest. A new academic year is getting underway for many of our readers, and regardless of the “new normal” imposed by COVID-19, the journal continues to publish groundbreaking research from across the immunotherapy field.
The articles spotlighted in this month’s digest exemplify how the immunotherapy field excels at bringing a new perspective to processes or therapies that might be considered familiar—thus advancing our discipline in novel and important new directions.
John C. Flickinger Jr., and colleagues creatively overcome the obstacle inherent in many cancer vaccine approaches of pre-existing host immunity to the adenoviral backbone by engineering a new chimeric vector.
By taking a new look at a familiar cytokine, Tal Kan et al provide evidence that IL-31 may induce anti-tumor immunity in breast cancer.
New immune response biomarkers that could help identify patients with melanoma who may benefit from combination radiotherapy and CTLA-4 blockade are described by Celine Boutros and colleagues. Additionally, evidence for safety and efficacy with retreatment with anti-PD-L1 therapy after discontinuation for reasons other than toxicity or progression is provided by Siddharth Sheth et al.
Although the results were negative for a first-in-human trial for a first-in-class, orally administered, selective dual inhibitor of IDO1 and TDO2, reported by Aung Naing and colleagues, the findings could set the stage for future studies of rational combinations of therapies targeting tryptophan metabolism and other immunotherapy agents.
Finally, a first-of-its-kind study by Pedro Barata et al demonstrates the feasibility of using a commercially available cell-free DNA assay to identify patients with advanced prostate cancer and microsatellite instability-high tumors who may benefit from pembrolizumab.
To further your reading this month, be sure to browse JITC’s Reading List, with an intriguing selection of papers drawn from the viral immunology world, selected by Dr. Howard Kaufman.
Best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
To view the entire September 2020 JITC Digest, please click here.
No comments:
Post a Comment